Hansa Biopharma — Februar 2023
-
Jeg har suppleret 14 gange under kurs 85 ultimo 22 samt her i 2023. Og ja en enkelt gang under kurs 50. Senest igen i går under kurs 55 og i åbningen i dag i ca. kurs 53.
Synes at regnskabet ser fint ud. At ting tager tid og trækker ud, er standard i biotek. -
Penser Access:
"Vårt nya motiverade värde är 210-220 kronor per aktie (240-250). Vi ser en fortsatt mycket stor uppsida i Hansa-aktien på sikt, men en tillväxt i produktförsäljning av Idefirix kommer att bli av yttersta vikt för att aktien ska prestera framöver".
-
Hansa Biopharma AB (publ) (HNSBF) Q4 2022 Earnings Call Transcript
Hansa Biopharma AB (publ) (OTCPK:HNSBF) Q4 2022 Earnings Conference Call February 2, 2023 8:00 AM ET
Company Participants
Søren Tulstrup - President and CEO
Donato Spota - SVP and CFO
Conference Call Participants
Gonzalo Attali - ABG Sundal Collier
Zoe Karamanoli - RBC Capital Markets
Christopher Uhde - SEB
Johan Unne
-
SEB höjer riktkursen för Hansa Biopharma till 260 kronor (230), upprepar köp – BN
[email protected]
Nyhetsbyrån Finwire -
Kopieret fra Genmab chatten. Nr. 2 er god læsning :-).https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2023?itm_source=parsely-api
-
Hansa virker “forpestet”
ALLE stigninger bliver omgående neutraliseret af et udsalg. Tålmodighed, men lidt frustrerende at se sælgerne kaste sig over aktien efter lidt stigning. -
Interresant artikel med brug af Imlifidase udenfor nyre transplantation. Brugt off-label til en patient med AML (Acute myeloid leukemia). Imlifidase virkede som det skulle (som sædvanligt).https://ashpublications.org/blood/article/140/Supplement 1/8562/489191/Successful-Desensitization-of-Severe-Alloimmune
-
Hansa Biopharma: Update ahead of 2023 – Gradual progress ahead
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months.
-
We make a slight negative revision after the recent Q4 result, and the most significant change is the number of shares relating to funding protecting the equity levels.
Our Base Case is SEK 170 (410) with a Bull Case of SEK 400 (600) and a Bear Case of SEK 45 (175).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind